Tarsus Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Nov 04, 2025, TARS reported earnings of -0.30 USD per share (EPS) for Q3 25, beating the estimate of -0.35 USD, resulting in a 16.06% surprise. Revenue reached 118.70 million, compared to an expected 117.53 million, with a 1.00% difference. The market reacted with a -4.62% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 147.53 million USD, implying an decrease of -70.00% EPS, and increase of 24.29% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Tarsus Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Tarsus Pharmaceuticals, Inc. Common Stock reported EPS of -$0.30, beating estimates by 16.06%, and revenue of $118.70M, 1% above expectations.
How did the market react to Tarsus Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.62%, changed from $71.50 before the earnings release to $68.20 the day after.
When is Tarsus Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 23, 2026.
What are the forecasts for Tarsus Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 11
analysts, Tarsus Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $147.53M for Q4 2025.